Rajni Dhalaria, Khomaizon Abdul Kadir Pahirul Zaman, Mehak Thakur, Sumayya Sana Shaikh, Renata Knop, Ayaz Mukarram Shaikh, Asgar Ali
{"title":"Synergistic relationship between plant extracts, essential oils, phytocompounds and antibiotics in controlling drug resistant bacterial species","authors":"Rajni Dhalaria, Khomaizon Abdul Kadir Pahirul Zaman, Mehak Thakur, Sumayya Sana Shaikh, Renata Knop, Ayaz Mukarram Shaikh, Asgar Ali","doi":"10.1186/s43088-026-00815-1","DOIUrl":"10.1186/s43088-026-00815-1","url":null,"abstract":"<div><h3>Background</h3><p>Antimicrobial resistance (AMR) has emerged as a global threat to global public health, requiring innovative strategies to address antibiotic-resistant bacterial pathogens. The synergy between plant extracts, essential oils, phytocompounds, and antibiotics promises to be a viable solution to this grave issue.</p><h3>Main body</h3><p>In addition to the synergistic effects of plant extracts, essential oils, and phytocompounds, the current review described the main groups of phytochemicals that function as anti-bacterial agents. The mechanical and toxicological issues are also highlighted in the current review.</p><h3>Conclusion</h3><p>The most popular techniques examined in this review are checkerboard and time-kill tests. The synergistic actions of plant extracts, phytocompounds, and essential oils effectively reduced the drug’s minimal inhibitory concentration against both standard and clinical bacterial isolates. Each of the three complementary strategies-plant extracts, phytocompounds, and essential oils-was equally significant.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00815-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148926486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Targeted nanocarriers in gastric cancer: a critical review of HER2, CLDN18.2 and EGFR-directed translational evidence","authors":"Guoying Jiang, Guobing Wang, Jun Tao, Wenqi Feng","doi":"10.1186/s43088-026-00822-2","DOIUrl":"10.1186/s43088-026-00822-2","url":null,"abstract":"<div><h3>Purpose</h3><p>Targeted nanocarriers are increasingly proposed to overcome therapeutic resistance and peritoneal recurrence in gastric cancer (GC), yet clinical translation remains limited and, in our reading, systematically over-promised. This review addresses three conflated questions: whether HER2, CLDN18.2, and EGFR function not only as disease targets but as reliable nanocarrier gateways; which delivery barriers are realistically engineerable rather than merely describable; and why preclinical efficacy has rarely advanced to clinical benefit despite a decade of activity.</p><h3>Methods</h3><p>A structured narrative search of PubMed, Web of Science, and Google Scholar identified English-language literature (January 2014–April 2026) on GC nanocarriers, platforms, molecular targeting, trial registries (ClinicalTrials.gov) and translational nanomedicine. From 1,247 records, 186 GC-relevant studies were retained and classified across evidentiary tiers, and re-read for what they omitted—untargeted controls, quantitative biodistribution, orthotopic or peritoneal-metastasis modelling, and molecular-subtype stratification.</p><h3>Results</h3><p>HER2-directed nanocarriers are constrained by intratumoral heterogeneity and dynamic target loss, with most positive data from uniformly HER2-high cell lines. CLDN18.2 offers stronger specificity but faces assay-dependent prevalence, tight-junction sequestration limiting ligand access, and accelerating antibody-drug conjugate (ADC) competition. EGFR remains exploratory, as antibody failure (EXPAND, REAL3) is unreconciled with nanocarrier reuse and normal-tissue expression imposes a toxicity ceiling. Across platforms, nanoformulation reproducibly improves tolerability but rarely enhances intratumoral delivery, often reflecting solubilizer removal rather than a true “nano-effect”. Progress is further limited by overreliance on subcutaneous xenografts and near-absent integration of subtype, route, and manufacturability.</p><h3>Conclusion</h3><p>GC nanomedicine should shift from platform enthusiasm to disease-specific translational discipline. Intraperitoneal nanocarriers for peritoneal metastasis carry the highest near-term potential, whereas heterogeneity-ignoring HER2 and ADC-ignoring CLDN18.2 monotherapy programmes, and the emphasis on multi-stimuli-responsive and exosome-based delivery, risk being overstated. Future studies require route-specific design, subtype-guided selection, targeted-versus-untargeted controls, quantitative biodistribution, orthotopic/peritoneal validation, and an agreed minimum translational dataset.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00822-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148926693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"An overview of bioinformatics approaches to understand drug resistance and identifying novel inhibitors against multidrug-resistant Mycobacterium tuberculosis","authors":"Elizabeth Annie George, Mahima Senthilkumar, Kavitha Thirupugazh, Shivani Rajesh, Mahasaraswathi Chockalingam, Sudha Ramaiah, Anand Anbarasu","doi":"10.1186/s43088-026-00825-z","DOIUrl":"10.1186/s43088-026-00825-z","url":null,"abstract":"<div><h3>Background</h3><p>The rapid emergence of multidrug-resistant <i>Mycobacterium tuberculosis</i> (MDR-TB) has significantly reduced the effectiveness of conventional therapeutic regimens necessitating the discovery of novel drug targets and inhibitors.</p><h3>Main Body</h3><p>Recent bioinformatics-driven approaches for identifying putative inhibitors targeting essential mycobacterial proteins are comprehensively reviewed. Unlike previous reviews that tend to focus either on drug resistance mechanisms or drug discovery using computational approaches separately, this review integrates both aspects by linking genetic mutations associated with drug resistance and advanced computational approaches for anti-TB drug discovery. Integrative computational strategies including subtractive genomics, molecular docking, molecular dynamics simulations and machine learning-based prioritisation are emphasised. These approaches enable the identification of pathogen specific targets with minimal homology with the host proteins. This review further highlights the importance of natural products, peptides and drug repurposing strategies in targeting MDR-TB. Computational pipelines have shown the potential to greatly speed up early-stage drug discovery while lowering related costs and time, despite the challenges. The benefits of combining multi-omics data with artificial intelligence to create strain-specific treatment approaches are further demonstrated by case-based insights. Furthermore, this review highlights the current challenges in translating computational predictions into experimental and clinical validation while providing future directions including AI/ML based drug discovery, network pharmacology, host-directed therapies, and personalized medicine.</p><h3>Conclusion</h3><p>Overall, this review underscores the critical role of bioinformatics in addressing the global burden of MDR-TB and highlights its transformative role in guiding next-generation anti-TB drug development.</p><h3>Clinical trial number</h3><p>Not applicable.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00825-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148928042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hekmat El-gammal, Noriya Ebeed, Kadry El-Bakry, Ayman Hyder
{"title":"Antidiabetic action of Cleome droserifolia through direct interaction with pancreatic islet beta cell FABP3","authors":"Hekmat El-gammal, Noriya Ebeed, Kadry El-Bakry, Ayman Hyder","doi":"10.1186/s43088-026-00830-2","DOIUrl":"10.1186/s43088-026-00830-2","url":null,"abstract":"<div><h3>Background</h3><p><i>Cleome droserifolia</i> (Forssk.) Delile (Cleomaceae) is traditionally used in Egypt and other countries to manage a variety of diseases, including diabetes. Its antihyperglycemic effect is unconvincingly linked to its general antioxidant and anti-inflammatory effect. More specific antidiabetic mechanisms remain unexplored. In this context, fatty acid binding protein 3 (FABP3) is expressed by pancreatic islet beta cells; suppression of this protein has been shown to shield beta cells from lipotoxicity. This work investigates the possible relation of <i>C. droserifolia</i> bioactive components to FABP3 and its direct effects on pancreatic islets of a type 2 diabetes animal model.</p><h3>Methods</h3><p>Here, fractionated constituents of <i>C. droserifolia</i> were evaluated for their possible binding to FABP3 by in silico molecular docking. Four-week-old rats were fed a high-fat/high-fructose diet (HFHFD) mixed with aqueous or ethanolic extract of <i>C. droserifolia</i> for 16 weeks to investigate the effect on the glycemic and lipidemic states during the development of the diabetic model.</p><h3>Results</h3><p><i>Cleome droserifolia</i> inhibited the progression of HFHFD-induced obesity, hyperglycemia, hyperinsulinemia, impaired glucose tolerance test, insulin resistance, and dyslipidemia. Molecular docking results showed that many compounds of <i>C. droserifolia</i>, such as cleomaldeic acid, cleomeolide, luteolin, kaempferol, amblyone, and brachycarpone, can strongly bind onto FABP3 and occupy its binding pocket. In beta cells of rats, which concurrently fed HFHFD and <i>C. droserifolia</i>, fewer lipid droplets, immune cell infiltration, inflammatory, and apoptotic responses were observed.</p><h3>Conclusion</h3><p>Components of <i>C. droserifolia</i> competitively inhibit the binding of FABP3 with native fatty ligands, limiting lipid-induced deterioration of beta cells. The antidiabetic action of <i>C. droserifolia</i> can be attributed to this direct beneficial effect on pancreatic islet beta cells.</p><h3>Clinical trial number</h3><p>Not applicable.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00830-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148837576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shubham Atal, Santenna Chenchula, P. Ponmani, Jai Kumar Chaurasia, Malaya Nanda, K. Chandrahasan, Arti Shrivastava, S. Balakrishnan
{"title":"Anti-inflammatory and inflammation-associated pain-modulating effects of azilsartan in preclinical models","authors":"Shubham Atal, Santenna Chenchula, P. Ponmani, Jai Kumar Chaurasia, Malaya Nanda, K. Chandrahasan, Arti Shrivastava, S. Balakrishnan","doi":"10.1186/s43088-026-00823-1","DOIUrl":"10.1186/s43088-026-00823-1","url":null,"abstract":"<div><h3>Introduction</h3><p>Azilsartan, an angiotensin receptor blocker, has been widely used in the treatment of hypertension. Its unique structure is hypothesised to confer multiple pleiotropic effects, including anti-inflammatory and anti-apoptotic properties, with potential antioxidant effects being exploratory. The present study was conducted to evaluate the anti-inflammatory, antinociceptive, and antioxidative properties of azilsartan in thermally and chemically induced nociceptive rodent models.</p><h3>Materials and methods</h3><p>Wistar albino rats (200–250 g) and Swiss albino mice (25–30 g) of either sex were procured from the Central Animal Facility, AIIMS Bhopal. Two doses of azilsartan (1 mg/kg and 4 mg/kg) were investigated after approval from the institutional animal ethics committee. Anti-inflammatory and anti-nociceptive properties were evaluated using chemically induced inflammatory models, including carrageenan, Freund’s complete adjuvant (FCA)-induced arthritis, thermally induced nociceptive models and Aspirin-induced gastric ulcer.</p><h3>Results</h3><p>Azilsartan produced significant anti-inflammatory effects in chemically induced models. In the carrageenan-induced paw edema model, at 6 h, paw volume was reduced to 1.59 ± 0.02 ml with azilsartan 4 mg/kg vs. 1.86 ± 0.01 ml in controls (32% inhibition, <i>p</i> < 0.01). In the FCA-induced arthritis model, by day 14, joint size was reduced by 27% with azilsartan 4 mg/kg (<i>p</i> < 0.05 vs. control). Histopathological and immunohistochemical analyses demonstrated reduced inflammatory infiltration and decreased TNF-α expression in azilsartan-treated groups. Azilsartan also showed dose-dependent protection against aspirin-induced gastric ulceration, with 36% and 45% inhibition at doses of 1 and 4 mg/kg, respectively (<i>p</i> < 0.001). Mean MDA levels were 350 pg/mL in controls vs. 115 pg/mL with azilsartan 4 mg/kg (<i>p</i> = 0.12). No significant analgesic effect was observed in thermally induced nociceptive models (hot plate and tail flick tests).</p><h3>Conclusion</h3><p>Azilsartan exhibits significant anti-inflammatory and inflammation-associated pain–modulating effects in preclinical models, but does not demonstrate significant analgesic activity in acute thermal nociception.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div><h3>Clinical trial number</h3><p>Not applicable.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00823-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148837598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maryam Rezaee, Farideh Izadi, Saeed Nobaharian, Leila Hassani, Esmaeil Rezaei, Sara Sadeghi Amini, Ali Akbar Pourfathollah, Ali Kowsari, Sirous Naeimi, Khalil Khashei Varnamkhasti, Leila Rouhi
{"title":"Therapeutic CRISPR/Cas9 delivery approaches: strengths, limitations, and a roadmap for clinical translation","authors":"Maryam Rezaee, Farideh Izadi, Saeed Nobaharian, Leila Hassani, Esmaeil Rezaei, Sara Sadeghi Amini, Ali Akbar Pourfathollah, Ali Kowsari, Sirous Naeimi, Khalil Khashei Varnamkhasti, Leila Rouhi","doi":"10.1186/s43088-026-00824-0","DOIUrl":"10.1186/s43088-026-00824-0","url":null,"abstract":"<div><h3>Background</h3><p>CRISPR/Cas9 has revolutionized genetic engineering since its repurposing as a programmable nuclease in 2012, yet its clinical translation remains fundamentally constrained by delivery barriers rather than editing efficiency. The system operates through acquisition, biogenesis, and interference mechanisms, but therapeutic application necessitates overcoming delivery challenges that are highly context-dependent.</p><h3>Main body</h3><p>This review moves beyond a descriptive summary of 67 studies to provide a critical, barrier-focused analysis of delivery strategies. Our re-analysis of the tabulated data identifies quantitative trends across viral, non-viral, and physical platforms, evaluates trade-offs between efficiency and safety, and proposes a decision framework for vehicle selection based on target tissue and cargo type. A major focus of this review is the inclusion of recent hybrid systems (VLPs, SORT-LNPs) and the recognition that chemical modification of guide RNAs is a critical parameter for therapeutic success. A key forward-looking insight is that hybrid systems and stimuli-responsive nanoparticles are poised to dominate the next 5 years of clinical development, particularly for liver, CNS, and hematopoietic targets.</p><h3>Conclusion</h3><p>Successful clinical translation of CRISPR/Cas9 will depend on context-specific delivery strategies that balance editing efficiency, safety, and clinical scalability.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00824-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148783208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Harsh Kumar, Kamil Kuca, Nidhi Sethi, Mehak Thakur, Mohd Tariq, Hasnita Binti Che Harun, Lukas Peter, Marek Zdaniewicz, Ayaz Mukarram Shaikh, Béla Kovács, Endre Harsányi
{"title":"Postharvest management of fungal pathogens of selected fruits: role of plant extracts, essential oils, edible films/coatings, and green nanoparticles","authors":"Harsh Kumar, Kamil Kuca, Nidhi Sethi, Mehak Thakur, Mohd Tariq, Hasnita Binti Che Harun, Lukas Peter, Marek Zdaniewicz, Ayaz Mukarram Shaikh, Béla Kovács, Endre Harsányi","doi":"10.1186/s43088-026-00821-3","DOIUrl":"10.1186/s43088-026-00821-3","url":null,"abstract":"<div><h3>Background</h3><p>Fruits such as mango (<i>Mangifera indica</i>), apple (<i>Malus × domestica</i> ), tomato (<i>Solanum lycopersicum</i>), and strawberry (<i>Fragaria × ananassa</i>), are consumed worldwide and fall under a highly economical category of crops. In contrast, the postharvest management against fungal infections particularly remains a challenge for maintaining the quality standards of these fruits. For decades, farmers have been dependent upon synthetic fungicides, thus having a serious impact on human health as well as the overall ecosystem. In order to avoid such situations, diverse research laboratories around the world have discovered safe alternatives to these chemical fungicides.</p><h3>Main body</h3><p>The current review aims to summarize as well as analyze the substitute postharvest treatments, including plant extracts, edible films/coatings, green metallic nanoparticles, and plant-based essential oils for controlling fungal infections. The review also highlights the challenges related to each methodology.</p><h3>Conclusion</h3><p>Natural fungicides effectively kill or inhibit postharvest fungi in addition to maintaining the overall fruit quality that is of utmost importance for retailers, farmers, and ultimate consumers.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00821-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148751722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effects of red clover (Trifolium pratense L.) on type 2 diabetes mellitus parameters: a systematic review","authors":"Atefeh Amerizadeh, Fatemeh Rafieian, Mohammad Hossein Paknahad, Fatemeh Moslemi, Hooria Seyedhosseini-Ghaheh","doi":"10.1186/s43088-026-00820-4","DOIUrl":"10.1186/s43088-026-00820-4","url":null,"abstract":"<div><h3>Background</h3><p>Red clover (<i>Trifolium pratense</i>) and its isoflavones (formononetin, biochanin A) have been investigated for their potential effects on glucose metabolism and related metabolic outcomes.</p><h3>Methods</h3><p>A comprehensive systematic search was conducted according to PRISMA guidelines by searching PubMed, Web of Science, Embase, Scopus, and Google scholar for studies evaluating the effects of red clover extracts or isolated isoflavones on glycemic outcomes. Human, animal, and in vitro studies were included.</p><h3>Results</h3><p>Sixteen studies (18 datasets) met eligibility criteria, including 3 human studies, 11 animal studies, and 4 in-vitro studies. The in vitro studies consistently demonstrated favorable effects of red clover on glucose metabolism, including enhanced β-cell viability, reduced apoptosis, increased insulin secretion, and activation of metabolic pathways such as PPAR-α. Animal studies generally reported improvements in glycemic control and insulin sensitivity, including reductions in fasting glucose and HbA1c and modulation of metabolic regulators such as SIRT1. In contrast, evidence from human trials was limited and inconsistent. Only one randomized controlled trial reported a significant improvement in fasting insulin, whereas no consistent effects were observed for fasting glucose or HbA1c across studies. Interpretation of the clinical evidence is limited by the small number of trials, small sample sizes, and heterogeneity in study populations, interventions, and outcome measures.</p><h3>Conclusion</h3><p>Preclinical findings suggest that red clover may exert glucose-lowering and insulin-sensitizing effects; however, these findings have not been consistently confirmed in human studies. High-quality, adequately powered randomized controlled trials using standardized red clover preparations are required to establish its efficacy and safety in metabolic disease management.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00820-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148751724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maria Daniela Ionica Mihaila, Mihaela Dragoi Cudalbeanu, Bianca Furdui, Rodica Mihaela Dinica
{"title":"Phytochemistry and biological effects of aquatic plants from Danube Delta Biosphere Reserve (Iris spp. and Nymphaea spp.):an update review","authors":"Maria Daniela Ionica Mihaila, Mihaela Dragoi Cudalbeanu, Bianca Furdui, Rodica Mihaela Dinica","doi":"10.1186/s43088-026-00814-2","DOIUrl":"10.1186/s43088-026-00814-2","url":null,"abstract":"<div><h3>Background</h3><p>Among the native flora of the Danube Delta Biosphere Reserve in Romania, there are two beautiful aquatic flowering plants, the Yellow Flag Iris (<i>Iris pseudacorus</i>) and the White Waterlily <i>(Nymphaea alba</i>), which are part of the <i>Iris</i> and <i>Nymphaea</i> species, respectively. These two species, known mainly as ornamental plants, also have numerous bioactive properties, their extracts being recorded since the medieval era for the prevention and treatment of various diseases.</p><h3>Main body of the abstract</h3><p>This systematic review presents an update of the specialized literature on <i>Iris</i> spp. and <i>Nymphaea</i> spp. aiming to illustrate the chemical composition of the plant and a synthetic presentation of the most common biological applications of the extracts of these plants, but also regarding their traditional uses. Therefore, continued knowledge in this field is useful because there are few studies that reveal the toxicity of these plants at low doses.</p><h3>Conclusions</h3><p>The reviewed studies indicate that Iris and Nymphaea from the Danube Delta Biosphere Reserve contain a variety of bioactive compounds such as polyphenols, flavonoids and terpenoids that have supported many of their applications in traditional medicine, such as strong antioxidants, anti-inflammatory, antidiabetic, antitumor, antibacterial, antihepatotoxic, and antiviral activities.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00814-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148751396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meykson Alexandre da Silva, José Rivaldo de Lima, Jeanderson Marcelino da Silva, João Victor de Oliveira Alves, Marcia Vanusa da Silva, Hércules Melo Diógenes, Sarah Mikaella Silva de Brito, Roberta Jeane Bezerra Jorge, Maria Tereza dos Santos Correia
{"title":"Geographical distribution, ethnobotanical uses, phytochemical composition, and biological activities of Syagrus species from Northeastern Brazil","authors":"Meykson Alexandre da Silva, José Rivaldo de Lima, Jeanderson Marcelino da Silva, João Victor de Oliveira Alves, Marcia Vanusa da Silva, Hércules Melo Diógenes, Sarah Mikaella Silva de Brito, Roberta Jeane Bezerra Jorge, Maria Tereza dos Santos Correia","doi":"10.1186/s43088-026-00817-z","DOIUrl":"10.1186/s43088-026-00817-z","url":null,"abstract":"<div><p>This study aimed to perform an integrative review of ethnobotanical uses, biological activities, and phytochemical profiles of <i>Syagrus</i> species found in northeastern Brazil, and to assess their geographic distribution. The review was conducted using PubMed, Scopus, SciELO, and ScienceDirect, and selected studies published between 2011 and September 2025. The search strategy included scientific names of 25 species and hybrids. Peer-reviewed articles were included when <i>Syagrus</i> appeared in the title, abstract, or keywords, while duplicates and unrelated studies were excluded. Ethnobotanical reports, phytochemical data, and biological activities were analyzed systematically. Geographic distribution records from GBIF were processed in QGIS 3.22.1 to generate updated maps and identify new potential occurrence points. A total of 1,068 publications were identified, and after removing duplicates and applying eligibility criteria, 55 articles were included. Less than 15% of Brazilian <i>Syagrus</i> species (<i>n</i> = 9) have been scientifically investigated, indicating a significant knowledge gap. The fatty-acid profile of <i>Syagrus</i> oils is dominated by triacylglycerols containing medium- and long-chain fatty acids (C8–C24), with lauric acid (C12:0) frequently exceeding 40%. This composition underscores their pharmacological and industrial relevance, particularly for surfactant and detergent production. <i>Syagrus</i> species exhibit notable antioxidant, antimicrobial, antibiofilm, nematocidal, larvicidal, antiparasitic, analgesic, anti-inflammatory, anti-arthritis, and neuroprotective activities. Overall, <i>Syagrus</i> species from northeastern Brazil display strong ethnobotanical relevance and diverse bioactivities. However, research remains scarce, highlighting the need for further studies to isolate bioactive compounds and to support sustainable and safe therapeutic applications.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"15 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43088-026-00817-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148751395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}